EZH2 and glioblastoma: Taking into account the similar potencies of GSK126 and tazemetostat for EZH2 inhibition [17,50], this fact could explain the lower toxicity of tazemetostat compared to GSK126 in GBM cell lines, as observed in the aforementioned study investigating the effects of combining abemaciclib with EZH2 inhibitors [24].